GlaxoSmithKline (GSK) will partner with VBI Vaccines to study VBI’s LPV™ Platform, a formulation and process designed to help develop vaccines and biologics with improved stability and potency. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback